277 related articles for article (PubMed ID: 9301986)
1. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
Bouanchaud DH
J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
4. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
Dowzicky M; Nadler HL; Feger C; Talbot G; Bompart F; Pease M
Am J Med; 1998 May; 104(5A):34S-42S. PubMed ID: 9684656
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis.
Mouton JW; Endtz HP; den Hollander JG; van den Braak N; Verbrugh HA
J Antimicrob Chemother; 1997 May; 39 Suppl A():75-80. PubMed ID: 9511068
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
Hoogkamp-Korstanje JA; Roelofs-Willemse J
J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
[TBL] [Abstract][Full Text] [Related]
9. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Williams JD; Maskell JP; Whiley AC; Sefton AM
J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.
Chang SC; Fang CT; Hsueh PR; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):299-303. PubMed ID: 10212757
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
13. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
15. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
17. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
20. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
Tenover FC; Baker CN
J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]